943780-21-0

Basic information

• Product Name: 5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylic acid
• Synonyms: 5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylic acid
• CAS NO: 943780-21-0
• Molecular Weight: 437.546
• Mol File: 943780-21-0.mol

Chemical Properties

• CAS DataBase Reference: 5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylic acid(943780-21-0)
• EPA Substance Registry System: 5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylic acid(943780-21-0)

Safety Data

• Hazardous Substances Data: 943780-21-0(Hazardous Substances Data)

Upstream product

• 5782-69-4 6-isopropyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 55793-14-1 4-methyl-3-oxo-pentanal; sodium enolate 
• 943780-19-6 ethyl 5-(4-(((9H-fluoren-9-yl)methoxy)carbonylamino)phenylthio)-4-aminothiophene-2-carboxylate 
• 943780-18-5 ethyl 5-(4-(((9H-fluoren-9-yl)methoxy)carbonylamino)phenylthio)-4-nitrothiophene-2-carboxylate 
• 943771-02-6 N'-(3-cyano-6-isopropyl-pyridin-2-yl)-N,N-dimethyl-formamidine 
• 943771-00-4 2-bromo-6-isopropyl-nicotinonitrile 
• 5751-82-6 ethyl 5‐chlorothiophene‐2‐carboxylate 
• 89640-03-9 ethyl 5‐chloro‐4‐nitrothiophene‐2‐carboxylate 
• 563-80-4 3-methyl-butan-2-one 
• 943780-20-9 ethyl 5-(4-(((9H-fluoren-9-yl)methoxy)carbonylamino)phenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)thiophene-2-carboxylate 

Downstream Products

• 943780-16-3 (S)-5-(4-aminophenylthio)-4-(7-isopropylpyrido[2,3-d]pyrimidin-4-ylamino)-N-(2-phenylpropyl)thiophene-2-carboxamide 

Relevant articles and documents

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.